ReviewStem cells international2019
Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics.
Review in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.Frontiers in oncology · 2020Pooled it
- Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.Pediatric blood & cancer · 2020Trial
- Biology of stem cell paradox: a double-edged sword-implications for cancer therapy.Cancer cell international · 2025Review
- SF1, a Standardised Fraction fromThe Malaysian journal of medical sciences : MJMS · 2025Article
- miR-376a/Neuropilin-1 axis mediates the cancer stemness in oral squamous cell carcinoma-an in vitro study.Journal of dental sciences · 2025Article
- Extracting Knowledge from Machine Learning Models to Diagnose Breast Cancer.Life (Basel, Switzerland) · 2025Article
- Cancer stem cells and post-therapy tumour recurrence: a systematic review of mechanistic pathways and translational gaps.Ecancermedicalscience · 2025Review
- Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).International journal of oncology · 2024Review
- ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.Journal of experimental & clinical cancer research : CR · 2024Article
- The Role of Cancer Stem Cell Markers in Ovarian Cancer.Cancers · 2023Review
- The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential.International journal of molecular sciences · 2023Review
- PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.BMC cancer · 2023Article
- Multiple Myeloma Side Population Cells Promote Dexamethasone Resistance of Main Population Cells through Exosome Metastasis of LncRNA SNHG16.Journal of oncology · 2023Article
- Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (Review).Oncology letters · 2022Review
- A proto-telomere is elongated by telomerase in a shelterin-dependent manner in quiescent fission yeast cells.Nucleic acids research · 2022Article
- miR-509 inhibits cancer stemness properties in oral carcinomas via directly targeting PlK1.Journal of dental sciences · 2022Article
- Interaction between prostate cancer stem cells and bone microenvironment regulates prostate cancer bone metastasis and treatment resistance.Journal of Cancer · 2022Review
- miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer.Frontiers in oncology · 2022Article
- The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.Cancer metastasis reviews · 2021Review
- Tumor-associated macrophages in osteosarcoma.Journal of Zhejiang University. Science. B · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively. Tumor heterogeneity is, in part, controlled by cancer stem cells (CSC). CSC may be considered the reservoir of cancer cells as they exhibit properties of self-renewal and plasticity and the capability of reestablishing a heterogeneous tumor cell population. The endowed resistance mechanisms of CSC are mainly attributed to several factors including cellular quiescence, accumulation of ABC transporters, disruption of apoptosis, epigenetic reprogramming, and metabolism. There is a current need to develop new therapeutic drugs capable of targeting CSC to overcome tumor resistance. Emerging in vitro and in vivo studies strongly support the potential benefits of combination therapies capable of targeting cancer stem cell-targeting agents. Clinical trials are still underway to address the pharmacokinetics, safety, and efficacy of combination treatment. This review will address the main characteristics, therapeutic implications, and perspectives of targeting CSC to improve current anticancer therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.